Navigation Links
Gene therapy research switches off joint inflammation; switches on genetic process of joint repair

Scientists at Case Western Reserve University School of Medicine and Albany Medical College, together with Rainforest Nutritionals, Inc. have demonstrated in a mini symposium held today at the 14th International Conference of the Inflammation Research Association (IRA) that a blend of natural botanical products called Reparagen have turned on the master repair gene, IGF-1, which is responsible for growing human cartilage and restores joint function while blocking joint destruction associated with inflammation. The IRA is the preeminent meeting for inflammation investigators.

Mark J.S. Miller, Ph.D., M.B.A., Professor of Cardiovascular Sciences and Pediatrics at Albany Medical College (NY) and head of the Reparagen’s Scientific Advisory Board said that, "Sixty six million people have poor joint health; 20 million people suffer from osteoarthritis. Compromised joint health is a major contributor to comprised quality of life. No product of any kind has been able to demonstrate this combination of actions. These findings have been published in peer-review journals and presented to learned societies. The commercialization of Reparagen has been supported by the US government with a grant from the National Institutes of Health.

"Glucosamine is currently a gold standard in the natural product approach to joint health with $1 billion in annual sales but recent studies have questioned its effectiveness. There are no therapies on the market today that work by activating the genes that control the process of joint repair. Reparagen’s approach is unique, in that it switches ‘off?the genes that control joint destruction and inflammation while turning ‘on?the process of inserting glucosamine into new cartilage. Without this activated repair process glucosamine cannot be effective.1 So this solves a riddle that has plagued researchers for decades and corrects a problem that is exacerbated with aging.

Multi-center, Randomized controlled Clinical Trial Underway

Dr. Mark J.S. Miller said that, "This trial is important because it directly compares Reparagen with glucosamine in treating subjects with moderate osteoarthritis. Glucosamine is both familiar to consumers and healthcare providers and is the primary natural product approach to osteoarthritis."

The double blind randomized controlled clinical trial will assess a variety of pain, mobility and functional assessments in subjects with moderate osteoarthritis of the knee. Prior to this clinical investigation Reparagen was found to be the first natural product to "silence" genes that promote joint damage while simultaneously activating the repair gene, IGF-1, in human chondrocytes.2

The clinical study being conducted by clinical research organization Santerra Pharmaceuticals, LLC ( was submitted to Current Controlled Trials for review of the protocol and assignment of an International Standardized Randomized Controlled Trial Number (ISRCTN25438351).3

Rainforest Nutritionals, Inc. Vice President Paul Bobrowski emphasized that, "Reparagen continues to set a new standard in the joint health market, emphasized by this clinical study and the Current Controlled Trials validation." Elaborating Bobrowski said, "We believe that Reparagen’s unique mechanism of action and its NIH innovation Award makes it the alternative to glucosamine or chondroitin that consumers can trust and try".

Coauthor Paul Bobrowski emphasized that "If joints are like a brick wall made from bricks of glucosamine, and then it makes sense that to rebuild a functional wall that you need the master bricklayer and not just the simple approach of getting more bricks." Elaborating Bobrowski said, "By activating the joints master bricklayer Reparagen offers a more effective approach for regaining joint health."


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:

(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology: